Abstract:1. CNBP is associated with poor prognosis and clinical progression of neuroblastoma. 2. KPNB1 facilitates nuclear translocation of CNBP to interact with SMARCC2 in liquid condensates. 3. CNBP modulates SWI/SNF activity via SMARCC2 to drive ribosome biogenesis of neuroblastoma cells and subsequent M2 macrophage polarisation. 4. Therapeutic targeting of phase separation and interaction of CNBP with SMARCC2 inhibits neuroblastoma progression. Background Neuroblastoma (NB) is the most common extracranial malignancy in childhood; however, the mechanisms underlying its aggressive characteristics still remain elusive. Methods Integrative data analysis was performed to reveal tumour‐driving transcriptional regulators. Co‐immunoprecipitation and mass spectrometry assays were applied for protein interaction studies. Real‐time reverse transcription‐polymerase chain reaction, western blotting, sequential chromatin immunoprecipitation and dual‐luciferase reporter assays were carried out to explore gene expression regulation. The biological characteristics of NB cell lines were examined via gain‐ and loss‐of‐function assays. For survival analysis, the Cox regression model and log‐rank tests were used. Results Cellular nucleic acid‐binding protein (CNBP) was found to be an independent factor affecting NB outcome, which exerted oncogenic roles in ribosome biogenesis, tumourigenesis and aggressiveness. Mechanistically, karyopherin subunit beta 1 (KPNB1) was responsible for nuclear transport of CNBP, whereas liquid condensates of CNBP repressed the activity of switch/sucrose‐nonfermentable (SWI/SNF) core subunits (SMARCC2/SMARCC1/SMARCA4) via interaction with SMARCC2, leading to alternatively increased activity of SMARCC1/SMARCA4 binary complex in facilitating gene expression essential for 18S ribosomal RNA (rRNA) processing in tumour cells, extracellular vesicle‐mediated delivery of 18S rRNA and subsequent M2 macrophage polarisation. A cell‐penetrating peptide blocking phase separation and interaction of CNBP with SMARCC2 inhibited ribosome biogenesis and NB progression. High KPNB1, CNBP, SMARCC1 or SMARCA4 expression or low SMARCC2 levels were associated with poor survival of NB patients. Conclusions These findings suggest that CNBP phase separation is a target for inhibiting ribosome biogenesis and tumour progression in NB via modulating SWI/SNF complex activity.

SAPCD2 Promotes Neuroblastoma Progression by Altering the Subcellular Distribution of E2F7

CDK5RAP3 is a novel super-enhancer-driven gene activated by master TFs and regulates ER-Phagy in neuroblastoma

BRD4 Inhibitor GNE987 Exerts Anti-Cancer Effects by Targeting Super-Enhancers in Neuroblastoma

Single-cell RNA sequencing explored potential therapeutic targets by revealing the tumor microenvironment of neuroblastoma and its expression in cell death

Novel Mdm2 Inhibitor Sar405838 (Mi-773) Induces P53-Mediated Apoptosis in Neuroblastoma

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

Novel Src/Abl Tyrosine Kinase Inhibitor Bosutinib Suppresses Neuroblastoma Growth Via Inhibiting Src/Abl Signaling

EIF2S1 Silencing Impedes Neuroblastoma Development Through GPX4 Inactivation and Ferroptosis Induction

Downregulation of MEG3 and Upregulation of EZH2 Cooperatively Promote Neuroblastoma Progression.

Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity

Long Noncoding RNA NHEG1 Drives β-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5.

The Long Noncoding RNA Lncnb1 Promotes Tumorigenesis by Interacting with Ribosomal Protein RPL35

CDC27-ODC1 Axis Promotes Metastasis, Accelerates Ferroptosis and Predicts Poor Prognosis in Neuroblastoma

Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression.

EGCG Disrupts the LIN28B/Let-7 Interaction and Reduces Neuroblastoma Aggressiveness

NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1

A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways

NR1D1‐transactivated lncRNA NUTM2A‐AS1 promotes chemoresistance and immune evasion in neuroblastoma via inhibiting B7‐H3 degradation

Single-cell landscape analysis reveals distinct regression trajectories and novel prognostic biomarkers in primary neuroblastoma

IGF2BP1 regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis